Talphera reports Q4 2024 net loss $1.9M; FDA cuts NEPHRO study size to 70 patients

TALPHERA, INC.

2025-Q1 EPS reported -$0.10 revenue$27,000

FDA agreed to reduce NEPHRO CRRT study from 166 to 70 patients; study completion targeted by end of 2025.
Cash and investments of $8.9M at Dec 31, 2024; additional $14.8M private placement financing announced.
Q4 2024 net loss from continuing operations $1.9M ($0.07 per share) vs $4.5M ($0.25) in Q4 2023.
Combined R&D and SG&A expenses decreased to $3.0M in Q4 2024 from $4.6M in Q4 2023.
2025 cash operating expense guidance of $18M-$19M, includes costs to complete NEPHRO study.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.